Fibrinogen production is enhanced in an in-vitro model of non-alcoholic fatty liver disease: An isolated risk factor for cardiovascular events?

Lipids in Health and Disease

Volumn 14, Issue 1, 2015, Pages

  Yeung, Emily N W ^a   Treskes, Philipp ^a   Martin, Sarah F ^a   Manning, Jonathan R ^b   Dunbar, Donald R ^b   Rogers, Sophie M ^a   Le Bihan, Thierry ^a   Lockman, K Ann ^a   Morley, Steven D ^a   Hayes, Peter C ^a   Nelson, Leonard J ^a   Plevris, John N ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

C3A cells; Cardiovascular disease; Metabolic syndrome; Microarray; Non alcoholic fatty liver disease; Proteomics; STRING; Systems biology

Indexed keywords

FIBRINOGEN; FIBRINOGEN ALPHA CHAIN; FIBRINOGEN BETA CHAIN; FIBRINOGEN GAMMA CHAIN; UNCLASSIFIED DRUG; SQUALENE SYNTHASE;

ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; FDFT1 GENE; FGA GENE; FIBRINOGEN SYNTHESIS; GENE; GENE EXPRESSION; GENE IDENTIFICATION; HEPATOBLASTOMA CELL LINE; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; MICROARRAY ANALYSIS; NONALCOHOLIC FATTY LIVER; PROTEIN EXPRESSION; PROTEOMICS; RISK ASSESSMENT; RISK FACTOR; TRANSCRIPTION REGULATION; UPREGULATION; BIOLOGICAL MODEL; BIOSYNTHESIS; CARDIOVASCULAR DISEASES; COMPLICATION; DNA MICROARRAY; GENETIC ASSOCIATION STUDY; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CARDIOVASCULAR DISEASES; CELL LINE, TUMOR; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; FIBRINOGEN; GENETIC ASSOCIATION STUDIES; HUMANS; MODELS, BIOLOGICAL; NON-ALCOHOLIC FATTY LIVER DISEASE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOMICS; RISK FACTORS; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84938957456     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/s12944-015-0069-3     Document Type: Article

References (41)

1. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:6.
2. Feldstein AE. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis. 2010;30:4.
3. Farrell GC, Wong VWS, Chitturi S. NAFLD in Asia - as common and important as in the West. Nat Rev Gastrolenterol Hepatol. 2013;10:5.
4. Denis GV, Hamilton JA. Healthy obese persons: How can they be identified and do metabolic profiles stratify risk? Curr Opin Endocrinol Diabetes Obes. 2013;20:5.
5. Liu CJ. Prevalence and risk factors for NAFLD in Asian people who are not obese. J Gastroenterol Hepatol. 2012;27:10.
6. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population- based cohort study. Gastroenterology. 2005;129:1.
7. Harrison SA. Day CP Benefits of lifestyle modification in NAFLD. Gut. 2007;56:12.
8. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond). 2008;115:5.
9. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:9468.
10. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:4.
11. Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28- year follow-up. Hepatology. 2010;51:2.
12. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:6.
13. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini R, Zenari L, et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care. 2006;29:6.
14. Choi SY, Kim D, Kang JH, Park MJ, Kim YS, Lim SH, et al. Nonalcoholic fatty liver disease as a risk factor of cardiovascular disease: relation of non-alcoholic fatty liver disease to carotid atherosclerosis]. Korean J Hepatol. 2008;14:1.
15. Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007;13:10.
16. Lockman KA, Baren JP, Pemberton CJ, Baghdadi H, Burgess KE, Plevris-Papaioannou N, et al. Oxidative stress rather than triglyceride accumulation is a determinant of mitochondrial dysfunction in in vitro models of hepatic cellular steatosis. Liver Int. 2012;32:7.
17. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:10.
18. da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:1.
19. Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4:5.
20. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.
21. Le Bihan T, Martin SF, Chirnside ES, van Ooijen G, Barrios-Llerena ME, O'Neill JS, et al. Shotgun proteomic analysis of the unicellular alga Ostreococcus tauri. J Proteomics. 2011;74:10.
22. Rappsilber J, Mann M, Ishihama Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc. 2007;2:8.
23. Martin SF, Munagapati VS, Salvo-Chirnside E, Kerr LE, Le Bihan T. Proteome turnover in the green alga Ostreococcus tauri by time course 15 N metabolic labeling mass spectrometry. J Proteome Res. 2012;11:1.
24. Le Bihan T, Grima R, Martin S, Forster T, Le Bihan Y. Quantitative analysis of low-abundance peptides in HeLa cell cytoplasm by targeted liquid chromatography/mass spectrometry and stable isotope dilution: emphasising the distinction between peptide detection and peptide identification. Rapid Commun Mass Spectrom. 2010;24:7.
25. Eden E, Lipson D, Yogev S, Yakhini Z. Discovering motifs in ranked lists of DNA sequences. PLoS computational biology. 2007;3:3.
26. Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z. GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC bioinformatics. 2009;10:1.
27. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. 1995;Series B:Methodological.
28. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. The American journal of gastroenterology. 2009;104:4.
29. Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:14.
30. Lisman T, Weeterings C, de Groot PG. Platelet aggregation: involvement of thrombin and fibrin(ogen). Front Biosci. 2005;10:2504.
31. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. Jama. 2005;294:14.
32. Ndrepepa G, Braun S, King L, Fusaro M, Keta D, Cassese S, et al. Relation of fibrinogen level with cardiovascular events in patients with coronary artery disease. Am J Cardiol. 2013;111:6.
33. Hickman IJ, Sullivan CM, Flight S, Campbell C, Crawford DH, Masci PP, et al. Altered clot kinetics in patients with non-alcoholic fatty liver disease. Ann Hepatol. 2009;8:4.
34. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev. 2002;3:2.
35. Russo I. The Prothrombotic Tendency in Metabolic Syndrome: Focus on the Potential Mechanisms Involved in Impaired Haemostasis and Fibrinolytic Balance. Scientifica (Cairo). 2012;2012:525374.
36. Ghio AJ, Kim C, Devlin RB. Concentrated ambient air particles induce mild pulmonary inflammation in healthy human volunteers. Am J Respir Crit Care Med. 2000;162:3.
37. Pekkanen J, Brunner EJ, Anderson HR, Tiittanen P, Atkinson RW. Daily concentrations of air pollution and plasma fibrinogen in London. Occup Environ Med. 2000;57:12.
38. Lucking AJ, Lundback M, Mills NL, Faratian D, Barath SL, Pourazar J, et al. Diesel exhaust inhalation increases thrombus formation in man. Eur Heart J. 2008;29:24.
39. Filippi C, Pryde A, Cowan P, Lee T, Hayes P, Donaldson K, et al. Toxicology of ZnO and TiO2 nanoparticles on hepatocytes: Impact on metabolism and bioenergetics. Nanotoxicoloty. 2015;9:1.
40. Tornqvist H, Mills NL, Gonzalez M, Miller MR, Robinson SD, Megson IL, et al. Persistent endothelial dysfunction in humans after diesel exhaust inhalation. Am J Respir Crit Care Med. 2007;176:4.
41. Buczko W, Mogielnicki A, Kramkowski K, Chabielska E. Aspirin and the fibrinolytic response. Thrombosis Research. 2003;110:5-6.